Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 2
1981 1
1982 3
1983 3
1984 1
1985 5
1986 10
1987 12
1988 13
1989 16
1990 16
1991 21
1992 30
1993 38
1994 39
1995 52
1996 59
1997 62
1998 76
1999 74
2000 103
2001 88
2002 115
2003 139
2004 178
2005 219
2006 265
2007 285
2008 331
2009 402
2010 416
2011 550
2012 657
2013 768
2014 932
2015 1025
2016 1111
2017 1204
2018 1319
2019 1599
2020 1925
2021 2230
2022 2651
2023 2712
2024 3113
2025 3583
2026 746

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26,085 results

Results by year

Filters applied: . Clear all
Page 1
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A; CARES-310 Study Group. Qin S, et al. Among authors: lin x. Lancet. 2023 Sep 30;402(10408):1133-1146. doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24. Lancet. 2023. PMID: 37499670 Clinical Trial.
Early intensive blood pressure management after endovascular treatment in ischaemic stroke (IDENTIFY): a multicentre, open-label, blinded-endpoint, randomised controlled trial.
Zhang X, Cao L, Wu S, Wang D, Wang H, Zhang D, Wang J, Chen L, Lin X, Qian D, Zhang Q, Xiong L, Wang W, Tang Y, Lei B, Liu T, He J, Wang L, Guo F, Li G, Wang K, Li J, Luo J, Shen J, Xu M, Zheng H, Zhou D, Liu M, Hu F, Wu B; IDENTIFY Trial Investigators. Zhang X, et al. Among authors: lin x. Lancet Reg Health West Pac. 2025 Jun 6;59:101589. doi: 10.1016/j.lanwpc.2025.101589. eCollection 2025 Jun. Lancet Reg Health West Pac. 2025. PMID: 40538518 Free PMC article.
cellSTAAR: incorporating single-cell-sequencing-based functional data to boost power in rare variant association testing of noncoding regions.
Van Buren E, Zhang Y, Li X, Selvaraj MS, Li Z, Zhou H, Palmer ND, Arnett DK, Blangero J, Boerwinkle E, Cade BE, Carlson JC, Carson AP, Chen YI, Curran J, Duggirala R, Fornage M, Franceschini N, Graff M, Gu C, Guo X, He J, Heard-Cosa N, Hou L, Hung YJ, Kalyani RR, Kardia SLR, Kenny E, Kooperberg C, Kral BG, Lange L, Levy D, Li C, Liu S, Lloyd-Jones D, Loos RJF, Manichaikul AW, Martin LW, Mathias R, Minster RL, Mitchell BD, Mychaleckyj JC, Naseri T, North K, O'Connell J, Perry JA, Peyser PA, Psaty BM, Raffield LM, Vasan RS, Redline S, Reiner AP, Rich SS, Smith JA, Spitzer B, Tang H, Taylor KD, Tracy R, Viali S, Yanek L, Zhao W; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; Rotter JI, Peloso GM, Natarajan P, Lin X. Van Buren E, et al. Among authors: lin x. Nat Methods. 2026 Feb;23(2):338-349. doi: 10.1038/s41592-025-02919-5. Epub 2025 Dec 31. Nat Methods. 2026. PMID: 41476111
Harnessing phytochemicals for engineering health solutions.
Kim JJH, Yang TB, Zhang X, Lin X, Salethoor SN, Menon MM, Snyder MP. Kim JJH, et al. Among authors: lin x. Hum Genomics. 2026 Jan 22;20(1):36. doi: 10.1186/s40246-025-00882-y. Hum Genomics. 2026. PMID: 41572398 Free PMC article. Review.
26,085 results
You have reached the last available page of results. Please see the User Guide for more information.